

## LIDDS patent covering the NanoZolid® production process granted in Japan and South Korea

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence the achieved pharmaceutical products, has been granted in Japan and South Korea. The patent provides protection until 2037 in these markets.

“The expansion of our patent protection in two markets of significant size is an important step in our strategy to strengthen our commercial position in potential partner discussions” says Nina Herne, CEO of LIDDS.

Recently, LIDDS has received patent approval in Japan (JP2019520633A) and South Korea (KR20197011910A). The invention covering the production process for the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. This adds two important approvals for this patent family, which has also received approvals in China, Russia, Australia, India, South Africa and Singapore in recent times. The patent and a related divisional patent are already approved in the US as previously communicated.

### For additional information, please contact

---

Nina Herne, CEO  
Phone: +46 (0)70 714 74 57  
E-mail: [nina.herne@liddspharma.com](mailto:nina.herne@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB  
Tel: +46 (0)8 121 576 90  
E-mail: [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)

### LIDDS in brief:

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

## Attachments

---

**LIDDS patent covering the NanoZolid® production process granted in Japan and South Korea**